228 related articles for article (PubMed ID: 7306988)
1. Effects of 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride (Ticlopidine), a platelet aggregation inhibitor, on blood-borne metastasis.
Kohga S; Kinjo M; Tanaka K; Ogawa H; Ishihara M; Tanaka N
Cancer Res; 1981 Nov; 41(11 Pt 1):4710-4. PubMed ID: 7306988
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of platelet aggregation by a new agent, Ticlopidine.
Ashida SI; Abiko Y
Thromb Haemost; 1979 Feb; 40(3):542-50. PubMed ID: 425067
[TBL] [Abstract][Full Text] [Related]
3. Effects of DN-9693, a new metastasis inhibitor, on murine hematogenous metastasis.
Tanaka NG; Tohgo A; Ogawa H; Osada Y
Anticancer Res; 1986; 6(4):543-8. PubMed ID: 3019218
[TBL] [Abstract][Full Text] [Related]
4. Effects of ticlopidine on metastasis production in mice bearing Lewis lung carcinoma.
Fabra A; de Castellarnau C; Carretero F; Martínez E; Sancho MJ; Rutllant ML
Invasion Metastasis; 1987; 7(1):53-60. PubMed ID: 3583621
[TBL] [Abstract][Full Text] [Related]
5. Effects of antiplatelet agents on pulmonary metastases.
Bando H; Yamashita T; Tsubura E
Gan; 1984 Mar; 75(3):284-91. PubMed ID: 6724229
[TBL] [Abstract][Full Text] [Related]
6. Platelet-aggregating activities of metastasizing tumor cells. II. Variety of the aggregation mechanisms.
Tohgo A; Tanaka N; Ashida S; Ogawa H
Invasion Metastasis; 1984; 4(3):134-45. PubMed ID: 6480287
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of in vivo prostacyclin on the development of pulmonary metastases in mice following intravenous injection of CT26 colon carcinoma, Lewis lung carcinoma, or B16 amelanotic melanoma cells.
Karpatkin S; Ambrogio C; Pearlstein E
Cancer Res; 1984 Sep; 44(9):3880-3. PubMed ID: 6378376
[TBL] [Abstract][Full Text] [Related]
8. Study of platelet aggregation in vivo. IX. Effect of nafazatrom on in vivo platelet aggregation and spontaneous tumor metastasis.
Ambrus JL; Ambrus CM; Gastpar H; Williams P
J Med; 1982; 13(1-2):35-47. PubMed ID: 6288824
[TBL] [Abstract][Full Text] [Related]
9. Platelet-aggregating activities of metastasizing tumor cells. V. In situ roles of platelets in hematogenous metastases.
Tanaka NG; Tohgo A; Ogawa H
Invasion Metastasis; 1986; 6(4):209-24. PubMed ID: 3759361
[TBL] [Abstract][Full Text] [Related]
10. [Cancer blood-borne metastasis and platelets].
Tanaka K; Fukumoto S
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2453-9. PubMed ID: 6391385
[TBL] [Abstract][Full Text] [Related]
11. [Effects of platelet aggregating inhibitor on pulmonary metastases of tumor cells after surgical resection].
Yano S
Hokkaido Igaku Zasshi; 1993 Sep; 68(5):654-63. PubMed ID: 8225173
[TBL] [Abstract][Full Text] [Related]
12. Anti-platelet drugs during chronic hemodialysis: an experience with ticlopidine, the 5-(o-chlorobenzyl)-4,5,6,7-tetrahydrothieno-[3,2-c] pyridine.
Bono F; De Gasperi T; Zanelli P; Menta R; Castiglioni A; Savazzi GM; Cambi V
Farmaco Prat; 1983 Dec; 38(12):451-5. PubMed ID: 6662220
[No Abstract] [Full Text] [Related]
13. Effect of Avemar and Avemar + vitamin C on tumor growth and metastasis in experimental animals.
Hidvégi M; Ráso E; Tömösközi-Farkas R; Paku S; Lapis K; Szende B
Anticancer Res; 1998; 18(4A):2353-8. PubMed ID: 9703878
[TBL] [Abstract][Full Text] [Related]
14. FCE 27266, a sulfonic distamycin derivative, inhibits experimental and spontaneous lung and liver metastasis.
Sola F; Farao M; Ciomei M; Pastori A; Mongelli N; Grandi M
Invasion Metastasis; 1995; 15(5-6):222-31. PubMed ID: 8765197
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological studies on ticlopidine, a new platelet aggregation inhibitor. Part I: Cardiovascular effects.
Akashi A; Tamura K; Hirohashi M; Watanabe K; Kasahara A
Arzneimittelforschung; 1980; 30(3):409-14. PubMed ID: 7387750
[No Abstract] [Full Text] [Related]
16. General pharmacology of the new antimuscarinic compound vamicamide.
Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
[TBL] [Abstract][Full Text] [Related]
17. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitory effect of tripeptide compound tyroservaltide on invasion and metastasis of mouse melanoma cell line B16-F10].
Che XC; Lu R; Hu JX; Zheng MN; Zhang MF; Wang S; Yu CY; Yang XL; Xing DH; Yao Z
Ai Zheng; 2006 Mar; 25(3):275-80. PubMed ID: 16536978
[TBL] [Abstract][Full Text] [Related]
19. Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine.
Bastida E; Escolar G; Almirall L; Ordinas A
Thromb Haemost; 1986 Jun; 55(3):333-7. PubMed ID: 3750263
[TBL] [Abstract][Full Text] [Related]
20. Suppressing effects of dietary supplementation of the organoselenium 1,4-phenylenebis(methylene)selenocyanate and the Citrus antioxidant auraptene on lung metastasis of melanoma cells in mice.
Tanaka T; Kohno H; Murakami M; Kagami S; El-Bayoumy K
Cancer Res; 2000 Jul; 60(14):3713-6. PubMed ID: 10919638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
